SiranBio was established in May 2022 in Suzhou Industrial Park. We are a biotech company specialized in siRNA drug development. Our core team is consisted of top scientists and pioneers of siRNA drugs in China. Several prestigious awards has been given to our company since its inception, such as The Leading Enterprise in Suzhou Industrial Park and as Gusu Leading Enterprise in 2002.

We have developed comprehensive and proprietary platform technologies which encompass the whole process of siRNA drug development, including siRNA sequence design and screening, chemical modifications for PD enhancement and off-target attenuation (eSAFE), liver and extrahepatic delivery (STORK), and dual-targeting siRNA. Based on these innovative technologies, we very quickly established a robust pipeline with potentials to become First-in-Class (FIC) and Best-in-Class (BIC) siRNA therapeutics for several important therapeutic areas, including anti-viral, cardiovascular and metabolic diseases, autoimmune diseases, CNS diseases.

We always put the patients’ needs in the highest priority, to innovate best siRNA drugs for the health and well-being of human kind.